1. Nat. Rev. Urol. doi:10.1038/nrurol.2016.175
Figure 1 Recurrent prostate cancer detected with PSMA-targeted 18F-DCFPyL PET–CT
Figure 1 | Recurrent prostate cancer detected with PSMA-targeted 18F-DCFPyL PET–CT. The patient presented approximately 5 years after radical prostatectomy with a serum PSA of 0.43 ng/ml and without evidence of disease on bone scan or contrast-enhanced CT. The (a) maximal intensity projection and (b) fused PET–CT axial images demonstrate recurrent disease in the transverse process of T7 (red arrows). The patient was successfully treated with stereotactic body radiation to the lesion.
Tosoian, J. J. et al. (2016) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations
Nat. Rev. Urol. doi: /nrurol